Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q1

3151.TEDINET S100RLIV
Period2023-04-01 → 2023-06-30
Filed2023-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥144.5bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥143.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.2bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥849m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.2bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥917m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥640m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥945m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥675m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥305.7bnat 2023-06-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥314.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥203.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥101.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥21.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥17.812023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥12.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.0%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.9%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥648m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥90m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥15m
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2023-04-01 → 2023-06-30¥138.7bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2023-04-01 → 2023-06-30¥135.9bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2023-04-01 → 2023-06-30¥1.1bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥4.7bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥87m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥99m
—segment totalrevenue2023-04-01 → 2023-06-30¥146.1bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥143.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥2.8bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥148.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥144.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥626m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥69m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue2022-04-01 → 2022-06-30¥138.4bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue external2022-04-01 → 2022-06-30¥135.6bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E22440-000Medicine Wholesalereportable segmentsegment profit2022-04-01 → 2022-06-30¥783m
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥14m
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.7bn
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥121m
—segment totalrevenue2022-04-01 → 2022-06-30¥145.5bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥142.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥2.8bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥919m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥147.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥143.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥850m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 362
ItemContextValueUnit
Operating incomePrior1YTDDuration849000000JPY
Operating incomeCurrentYTDDuration1167000000JPY
Interest income noiPrior1YTDDuration15000000JPY
Interest income noiCurrentYTDDuration13000000JPY
Dividends income noiPrior1YTDDuration185000000JPY
Dividends income noiCurrentYTDDuration167000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration24000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration18000000JPY
Other noiPrior1YTDDuration173000000JPY
Other noiCurrentYTDDuration147000000JPY
Non operating incomePrior1YTDDuration398000000JPY
Non operating incomeCurrentYTDDuration347000000JPY
Interest expenses noePrior1YTDDuration26000000JPY
Interest expenses noeCurrentYTDDuration22000000JPY
Rent expenses noePrior1YTDDuration20000000JPY
Rent expenses noeCurrentYTDDuration19000000JPY
Other noePrior1YTDDuration3000000JPY
Other noeCurrentYTDDuration2000000JPY
Non operating expensesPrior1YTDDuration49000000JPY
Non operating expensesCurrentYTDDuration43000000JPY
Ordinary incomePrior1YTDDuration1198000000JPY
Ordinary incomeCurrentYTDDuration1470000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration3000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration3000000JPY
Extraordinary incomePrior1YTDDuration3000000JPY
Extraordinary incomeCurrentYTDDuration3000000JPY
Loss on valuation of investment securities elPrior1YTDDuration55000000JPY
Loss on valuation of investment securities elCurrentYTDDuration42000000JPY
Soil removal expenses elPrior1YTDDuration62000000JPY
Soil removal expenses elCurrentYTDDuration－JPY
Other elPrior1YTDDuration2000000JPY
Other elCurrentYTDDuration0JPY
Extraordinary lossPrior1YTDDuration119000000JPY
Extraordinary lossCurrentYTDDuration42000000JPY
Income before income taxesPrior1YTDDuration1081000000JPY
Income before income taxesCurrentYTDDuration1431000000JPY
Income taxesPrior1YTDDuration406000000JPY
Income taxesCurrentYTDDuration486000000JPY
Profit lossPrior1YTDDuration675000000JPY
Profit lossCurrentYTDDuration945000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration35000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration27000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration640000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration917000000JPY
Profit lossPrior1YTDDuration675000000JPY
Profit lossCurrentYTDDuration945000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration2234000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2726000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-89000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-91000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass